The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: A meta-analysis of observational studies

Zhiling Wang¹, Jie Wang¹, Peijun Wang²*  
¹ Department of SICU. Affiliated Children’s Hospital of Zhengzhou University, Henan Children’s Hospital, Zhengzhou, Henan Province, China, ² General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Henan Provincial Cancer Hospital, Zhengzhou, Henan Province, China  
* doctorwangpeijun@163.com

Abstract

Background and aims
The clinical value of the prognostic nutritional index (PNI) in hepatocellular carcinoma (HCC) has been investigated in previous studies, but the results remain controversial. Here we present a meta-analysis to systematically review the association between PNI and HCC prognosis.

Method
PubMed, EMBASE, Web of Science databases were systematically searched to identify relevant studies. Data were abstracted independently by two reviewers. A meta-analysis was performed to determine the prognostic and clinic-pathological values of PNI in HCC patients. Odds ratios (ORs) and 95% confidence intervals (CIs) were extracted to estimate the association of PNI with survival and clinic-pathological characteristics, respectively.

Results
A total of eleven studies involving 3165 patients were analyzed. The pooled results indicated that low PNI is a significant predictor of poor 1-year, 3-year, 5-year OS (OR, 2.91, 4.05, 3.65; 95%CI, 2.30 to 3.70, 3.27 to 5.03, 2.96–4.50; P = 0.14, 0.22, 0.11 respectively) and disease-free survival (DFS) (OR,2.35, 2.57, 2.75; 95%CI, 1.71 to 3.23, 1.89 to 3.49,2.01 to 3.75; P = 0.39,0.04,0.11, respectively). Moreover, PNI is significantly associated with serum AFP, tumor recurrence, tumor size and TNM stages in HCC patients. However, PNI is not significantly associated with tumor number and the incidence of cirrhosis in HCC patients.

Conclusions
PNI is an independent predictive indicator of survival and associated with serum AFP, tumor recurrence, tumor size and TNM stages in HCC patients.
Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies [1], the third leading cause of cancer-related death in the world [2]. Unlike other solid malignancies, most hepatocellular carcinoma evolved from chronic liver disease, especially associated with liver cirrhosis result from viral hepatitis or ethanol consumption [3,4]. Despite remarkable development in early diagnosis, surgery, adjuvant chemotherapy, even liver transplantation, but the effect remains unsatisfactory because of the high recurrence rate or metastasis within 5 years after treatment in HCC patients [5]. Therefore, it is important to assess disease progression in a timely manner and guide clinical treatment to improve the survival of patients.

Immune-nutritional status has been demonstrated to be associated with prognosis in patients with various malignancies and inflammatory response was known to promote tumor growth, invasion, angiogenesis and metastasis [6–8]. Prognostic nutritional index (PNI) based on albumin concentration and lymphocyte count in the peripheral blood, is a simple and practical indicator of systemic inflammatory response [9]. Recently, emerging evidence has reported the prognostic value of PNI in hepatocellular carcinoma [10–12]. However, those studies that using the PNI for HCC prognosis reported inconsistent results, largely due to differences in inclusion criteria and sample sizes [13, 14], as a result, the correlation of PNI with survival in HCC patients remains controversial. The aim of this study is to perform a meta-analysis to determine whether PNI is a useful prognostic factor and assess the correlation between PNI and clinic-pathological parameters in HCC patients.

Materials and methods

Search strategy

PubMed; EMBASE and Web of Science databases were comprehensively searched for relevant studies published from 1980 to December 2017 with the following keywords: “hepatocellular carcinoma”, “hepatocellular tumor”, “hepatocellular malignance” and “Prognostic nutritional index”, “PNI” and “prognosis”, “survival”, “outcome”. No time and language restrictions were imposed. Additionally, the relevant literatures including all of the identified studies, reviews and editorials were also reviewed. All candidate studies were carried out by two independent reviewers (Zhiling Wang and Peijun Wang) and discrepancies were resolved by consensus.

Criteria for inclusion and exclusion. Studies that fulfilled the following criteria were considered eligible and selected into this article: (1) pathologic examination for diagnosis of hepatocellular carcinoma; (2) clinic-pathological and prognostic values of PNI in HCC was reported; (3) case-control studies design; (4) sufficient data to allow for estimation of the OS, DFS. Nonhuman hepatocellular carcinoma research studies, duplicate articles, abstracts, recurrent HCC, letters, case reports and meetings reports were excluded from the analysis. Two reviewers evaluated all candidate literature and resolved any disagreement by discussion.

Data extraction. Two independent investigators reviewed the publications and extracted the data from relevant identified: author’s first name, year of publication, country, sample size, TNM stages, follow-up period, cutoff value and outcomes.

Quality assessment. In the included studies, PNI was calculated on the basis of pretreatment laboratory data and was using the formula: 10×albumin value (g/dl) + 0.005×lymphocyte count in the peripheral blood. The quality of the included studies was assessed using the Newcastle-Ottawa quality assessment scale (NOS) and we considered studies awarded with 6 or higher were classified as high-quality studies [15].
Statistical analysis

Meta-analysis was conducted using Review Manager 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). The association of PNI with survival and clinic-pathological characteristics in HCC patients were performed using ORs and 95% CI. The estimates of ORs were weighted and pooled using the Mantel-Haenszel fixed effects model. Statistical heterogeneity was assessed using the Cochran’s Q and I² statistics, if I² ≥ 50% or/and P < 0.10 were used to indicate statistically significant heterogeneity and a random-effects model was applied. Otherwise, a fixed-effect model was used [16]. Publication bias was assessed by visual inspection of the funnel plot. All statistical tests were two-sided, and statistical significance was defined as P<0.05.

Results

Eligible studies

A total of 39 potentially relevant studies were retrieved from three databases by the initial search. A flow chart showing the study selection was presented in S1 Fig. The initial search identified 39 studies, of which eleven studies by comprising 3165 patients published from 2012 to 2017 were finally included in this meta-analysis [17–27]. Eight studies from China, Two studies from Japan and one from UK. Study characteristics are presented in S1 Table.

PNI and Overall survival (OS) in HCC

There eleven studies reported the prognostic value of PNI for OS. Eleven studies reported the 1-year OS, ten studies and eight studies described the 3-year OS, 5-year OS, respectively. The results indicated that low PNI is significantly associated with poor prognosis of 1-year, 3-year and 5-year OS, without heterogeneity (OR, 2.91, 4.05, 3.65; 95%CI, 2.30 to 3.70, 3.27 to 5.03, 2.96–4.50; I² = 33%, 24%, 0%; P = 0.14, 0.22, 0.11 respectively), these results suggested that low PNI predict a poor OS in HCC patients. (S2 Fig)

PNI and disease-free survival (DFS) in HCC

DFS was mentioned in four studies. The pooled estimate for DFS indicated low PNI is significantly associated with poor prognosis of 1-year, 3-year and 5-year DFS in HCC patients (S3 Fig). A random-effects model was applied to calculate the pooled OR and 95%CI because of significant heterogeneity (OR, 2.35, 2.57, 2.75; 95%CI, 1.71 to 3.23, 1.89 to 3.49, 2.01 to 3.75; I² = 0%, 68%, 55%; P = 0.39, 0.04, 0.11 respectively). The results indicating that low PNI is likely to predict shorter DFS.

Relationship between PNI and clinic-pathological features

PNI and tumor stage. Four studies presented the data that about PNI and tumor stage in HCC patients. Our results indicated that low PNI have lower incidence of I and II stage (OR = 1.9, 95% CI = 1.22–1.96, P < 0.01), but there have no statistically significance in the stage III and IV between high PNI group and low PNI group (OR = 0.74, 95% CI = 0.55–1.01, P = 0.06) (S4A Fig).

PNI and cirrhosis. Five studies reported the association between PNI and the incidence of cirrhosis, the pooled results indicated that PNI have no significant association with the incidence of cirrhosis (OR = 0.86, 95% CI = 0.65–1.12, P = 0.26) (S4B Fig).
**PNI and tumor number.** Six studies reported tumor number (single or multiple), the pooled results suggested that PNI have no correlation with tumor number in HCC patients (OR = 0.89, 95% CI = 0.45–1.75, P = 0.11) (S4C Fig).

**PNI and tumor size.** Tumor size(≥5cm or <5cm) was reported in 4 studies, the pooled result indicated that low PNI group have a higher incidence of large tumor (OR = 0.52, 95% CI = 0.40–0.67, P = 0.004) (S5A Fig).

**PNI and AFP.** Five studies provided data about the correlation between PNI and serum AFP, the pooled results suggested that low PNI group have a higher serum AFP than high PNI group (OR = 0.51, 95% CI = 0.32–0.8, P = 0.003) (S5B Fig).

**PNI and tumor recurrence.** Tumor recurrence was reported in four studies, the pooled results suggested that low PNI have a higher recurrence incidences (OR, 0.37; 95% CI 0.23 to 0.59; I² = 47%; P<0.01) (S5C Fig).

**Publication bias**
A funnel plot was used to assess the included studies for overt publication bias showed symmetry for OS and DFS (S6 Fig).

**Discussion**
Some studies reported that the prognosis of hepatocellular carcinoma patients have a close relation with tumor burden, liver function and body immune status [28, 29]. Currently, recurrence and metastasis of hepatocellular carcinoma is still the most important reason for treatment failure. There are some factors that lead to recurrence include tumor size, vascular invasion, liver function, cirrhosis, immune status and so on. To our knowledge, the prognostic and clinic-pathological value of PNI has recently been studied in patients with many malignancies. However, the prognostic and clinic-pathological role of PNI in HCC patients is still not reported. This is the first systematic review/meta-analysis to provide a prognostic role of PNI and the relationship between PNI clinic-pathological characteristics in patients with HCC.

Eleven non-randomized trials compared the prognostic effects of PNI in HCC patients. Our results indicated that low PNI is a poor prognostic factor for OS and DFS in patients with HCC. These pooled results suggested that high PNI is a beneficial to the survival of HCC patients and associated with more favorable outcomes such as lower AFP, lower recurrence, minor tumor size and better TNM. However, PNI does not compromise clinic-pathological features including tumor number and the incidence of cirrhosis. Given these data, a simple PNI was shown to be a promising predictor of survival in HCC patients.

Several potential mechanisms may reveal that why low PNI is associated with poor prognosis in HCC patients. First, more and more evidences confirm that systemic inflammatory response plays a significant role in the development and progression of HCC. PNI which is a combination of the albumin and total lymphocyte count, was initially used to evaluate the immunological and nutritional aspects of patients undergoing surgery of the gastrointestinal tract [30]. Low PNI may be the result of hypoalbuminemia and/or lymphocytopenia. Albumin as the main component of plasma proteins, hypoalbuminemia reflected the presence of cancer cachexia is caused by a sustained inflammatory response, either from the tumor itself or as a host reaction [31]. However, impaired synthetic functions accompanying cirrhosis needs to be considered as an additional determinant of reduced serum albumin. Lymphocytes are crucial components of the immune system, play an extremely important role in the biological behavior of HCC, such as initiation, proliferation, differentiation and metastasis [32, 33], affect the tumor microenvironment, prevent tumorigenesis and recurrence by generating cytokines and
causing the cytotoxic effect of cancer cell death [34], so antitumor effect induced by the cellular immunity of T lymphocytes decreased because of lymphocytopenia [35]. Therefore, PNI reflects both the nutritional and immunological status of the host and can be a predictor of prognosis in HCC patients. Indeed, our findings indicated that PNI was an independent prognostic factor on OS and DFS in HCC patients and consistent with the above evidences. Second, our results indicated that low PNI was associated with more advanced tumor features, such as tumor recurrence, tumor size, serum AFP and TNM. The present meta-analysis showed that PNI was related to tumor recurrence and TNM, which might be explained by the immunological status. However, the correlation between PNI and serum AFP worth further study.

The synthesis of albumin is involved in HCC patients accompanied with cirrhosis [36], so we studied the correlation between PNI and the incidence of cirrhosis, the pooled results indicated that there is no obvious correlation between PNI and the incidence of cirrhosis. Mengyun Ke et al found that PNI was associated with tumor number in HCC patients [37], we analyzed the six studies included in this meta-analysis, pooled results suggested that PNI have no correlation with tumor number in HCC patients.

There were several limitations in our meta-analysis. First, all the included studies were retrospective cohort studies. Second, we could not perform other subgroup analyses because of the limited number of studies included. Third, those studies included in this meta-analysis mainly from Asian countries, only one from Europe.

Conclusion
In summary, our study suggests that PNI may be a potential marker to predict the prognosis of HCC patients.

Supporting information
S1 Checklist. PRISMA checklist.
(DOC)

S1 Table. Characteristics of the included studies.
(TIF)

S1 Fig. Flow chart of literature search and study selection.
(TIF)

S2 Fig. Forest plots depicting 1-year OS, 3-year OS and 5-year OS reported in the included studies. ORs are shown with 95% CIs. CI: confidence interval.
(TIF)

S3 Fig. Forest plots depicting 1-year DFS, 3-year DFS and 5-year DFS reported in the included studies.
(TIF)

S4 Fig. Forest plots depicting tumor TNM (A), the incidence of cirrhosis (B) and tumor number (C).
(TIF)

S5 Fig. Forest plots depicting tumor size (A), serum AFP (B) and the incidence of recurrence (C).
(TIF)

S6 Fig. Begg’s Funnel plot for evaluation of publication bias in OS and DFS.
(TIF)
Author Contributions
Supervision: Jie Wang.
Writing – original draft: Zhiling Wang.
Writing – review & editing: Peijun Wang.

References
1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557–76. https://doi.org/10.1053/j.gastro.2007.04.061 PMID: 17570226
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90. https://doi.org/10.3322/caac.20107 PMID: 21296855
3. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838–51. https://doi.org/10.1016/S0140-6736(08)60383-9 PMID: 18328931
4. Berasain C, Castillo J, Perugorría MJ et al (2009) Inflammation and liver cancer: new molecular mechanisms. Ann N Y Acad Sci; 1155:206–221 https://doi.org/10.1111/j.1749-6632.2009.03704.x PMID: 19250206
5. Brux J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208–36. https://doi.org/10.1002/hep.20933 PMID: 16250051
6. Du XJ, Tang LL, Mao YP, et al. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med 2015; 13:364. https://doi.org/10.1186/s12967-015-0729-0 PMID: 26585371
7. Mohri Y, Inoue Y, Tanaka K et al (2013) Prognostic nutritional index predicts postoperative outcome in colorectal cancer. World J Surg 37:2688–2692. https://doi.org/10.1007/s00268-013-2156-9 PMID: 23844382
8. Lee DY, Hong SW, Chang YG, Lee WY, Lee B. Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer. 2013; 13:111–6. https://doi.org/10.5230/jgc.2013.13.2.111 PMID: 23844326
9. Onodera T, Goseki N, Kosaki G, et al. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients [J].Ni-hon GeGa Gakkai Zasshi,1984 , 84:1001–1005.
10. SI-JIA WU, YI-XIN LIN, HUI YE, et al. Lymphocyte to Monocyte Ratio and Prognostic Nutritional Index Predict Survival Outcomes of Hepatitis B Virus-Associated Hepatocellular Carcinoma Patients After Curative Hepatectomy. Journal of Surgical Oncology 2016; 114:202–210 https://doi.org/10.1002/jso.24297 PMID: 27199001
11. Peng Wei, Li Chuan, Wen Tian-Fu, et al. postoperative prognostic nutritional index is an independent predictor of survival in patients with small hepatocellular carcinoma. The American Journal of Surgery (2016) 212,122–127. https://doi.org/10.1016/j.amjsurg.2015.06.023 PMID: 26421412
12. Yamamura Kazuo, Sugimoto Hiroyuki, Kanda Mitsuro et al. Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci (2014) 21:682–688. https://doi.org/10.1002/jhp.114 PMID: 24829666
13. Ni Xiao-Chun, Yi Yong, Fu Yi-Peng, et al. Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma. Medicine (Baltimore). 2015 Sep; 94(36):e1486.
14. Yang Y, Gao P, Song Y et al. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: A meta-analysis. Eur J Surg Oncol. 2016 Aug; 42 (8):1176–82. https://doi.org/10.1016/j.ejso.2016.05.029 PMID: 27293109
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003; 327:557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120
16. Yan Deng, Zhixin Wang, Runchen Miao, et al. Prognostic significance of the preoperative prognostic nutritional index for hepatocellular carcinoma patients undergoing surgical resection. MODERN ONCOLOGY.2016;2107–2112.
17. Fei Ji1, Yao Liang, Shunjun Fu, et al. Prognostic value of combined preoperative prognostic nutritional index and body mass index in HCC after hepatectomy. HPB (Oxford). 2017 May 3. pii: S1365-182X(17)30569-5.
19. Okamura Yukiyasu, Ashida Ryo, Ito Takaaki, Sugiuera Teiichi, Mori Keita, Uesaka Katsuhiko. Preoperative Neutrophil to Lymphocyte Ratio and Prognostic Nutritional Index Predict Overall Survival After Hepatectomy for Hepatocellular Carcinoma. World J Surg (2015) 39:1501–1509. https://doi.org/10.1007/s00268-015-2982-z PMID: 25670038

20. Zhang Xiaoyun, Li Chuan, Wen Tianfu, Peng Wei, Yan Lunan, Yang Jiayin. Postoperative Prognostic Nutritional Index Predicts Survival of Patients with Hepatocellular Carcinoma within Milan Criteria and Hypersplenism. J Gastrointest Surg. https://doi.org/10.1007/s11605-017-3414-1 PMID: 28523484

21. Huang Junting, Xu Li, Luo Yaoling, He Fenyong, Zhang Yaojun, Chen Minshan. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol (2014) 31:883. https://doi.org/10.1007/s12032-014-0883-x PMID: 2453607

22. Chan, FRCPA Anthony W. H., Chan, FRCP Stephen L., et al. Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. Ann Surg Oncol (2015) 22:4138–4148. https://doi.org/10.1245/s10434-015-4516-1 PMID: 25801356

23. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). British Journal of Cancer (2012) 106, 1439–1445. https://doi.org/10.1038/bjc.2012.92 PMID: 22433965

24. Kinoshita A, Onoda H, Imaizumi H, Iwakuma A, Oishi M, Fushimi N, Koike K, Nishino H, Tajiri H. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. British Journal of Cancer (2012) 107, 988–993. https://doi.org/10.1038/bjc.2012.354 PMID: 22878374

25. Ni Xiao-Chun, Yi Yong, Yi Peng Fu, et al. Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma. Medicine. (2015) 94, 1486–1493.

26. He Chao-Bin, Lin Xiao-Jun. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLOS ONE. 2017 https://doi.org/10.1371/journal.pone.0174769.

27. SI-JIA WU, YI-XIN LIN HUI YE, FU-YU LI, XIAN-ZE XIONG, LIN-SHE NG CHENG. Lymphocyte to Monocyte Ratio and Prognostic Nutritional Index Predict Survival Outcomes of Hepatitis B Virus-Associated Hepatocellular Carcinoma Patients After Curative Hepatectomy. Journal of Surgical Oncology 2016; 114:202–210. https://doi.org/10.1002/jso.24297 PMID: 27199001

28. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005; 41 (4):707–716. https://doi.org/10.1002/hep.20363 PMID: 15795889

29. Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting survival in patients with hepatocellular carcinoma in Egypt. PLOS One. 6, 2014; 9 (3):e90929. https://doi.org/10.1371/journal.pone.0090929 PMID: 24603710

30. Nozoe T, Kimura Y, Ishida M, Saito M, Sugimachi K. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol. 2002; 28:396–400 PMID: 12099649

31. McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. The Proceedings of the Nutrition Society, 67(3):257–62. https://doi.org/10.1017/S00268-015-2982-z PMID: 18452641

32. Unit E, Marshall A, Gelson W, et al.: Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45:246–253. https://doi.org/10.1016/j.jhep.2005.12.027 PMID: 16580084

33. Mano Y, Aishima S, Fujita N, et al.: Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 2013; 80:146–154. https://doi.org/10.1159/000346196 PMID: 23364389

34. Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract. 2005; 20(4):369–376. https://doi.org/10.1177/0894491105020004369 PMID: 16207677

35. Wada Y, Nakashima O, Kutami R, Yamamoto O and Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998; 27:407–414. https://doi.org/10.1002/hep.510270214 PMID: 9462638

36. Sung Hoon Kim, Do Young Kim, Jin Hong Lim, et al. Role of splenectomy in patients with hepatocellular carcinoma and hypersplenism. ANZ J Surg 2013(83) 865–870.

37. Mengyun Ke1, Tao Xu2, Na Li, Yifan Ren, Aihua Shi, Yi Lv, Haiqi He. Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria. Oncotarget, 2016, Vol. 7, (No. 49): 81611–81620. https://doi.org/10.18632/oncotarget.13151 PMID: 27835570